Tweet
Nat Cancer
. 2022 Dec 21.
doi: 10.1038/s43018-022-00502-x. Online ahead of print.
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
Andrea Keppler-Hafkemeyer # 1 , Christine Greil # 2 , Paul R Wratil # 3 4 , Khalid Shoumariyeh # 2 5 , Marcel Stern # 3 , Annika Hafkemeyer 2 , Driti Ashok 2 , Alexandra Hollaus 6 , Gaia Lupoli 3 , Alina Priller 7 , Marie L Bischof 3 , Gabriele Ihorst 8 , Monika Engelhardt 2 , Reinhard Marks 2 , Jürgen Finke 2 , Hannah Bertrand 2 , Christopher Dächert 3 4 , Maximilian Muenchhoff 3 4 , Irina Badell 3 4 , Florian Emmerich 9 , Hridi Halder 6 , Patricia M Spaeth 3 , Percy A Knolle 4 7 , Ulrike Protzer 4 10 11 , Michael von Bergwelt-Baildon 5 6 , Justus Duyster 2 , Tanja N Hartmann 2 , Andreas Moosmann 4 5 6 10 , Oliver T Keppler 12 13
Affiliations
- PMID: 36543907
- DOI: 10.1038/s43018-022-00502-x
Abstract
Individuals with hematologic malignancies are at increased risk for severe coronavirus disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity are scarce. Here we present an observational study with expanded methodological analysis of a longitudinal, primarily BNT162b2 mRNA-vaccinated cohort of 60 infection-naive individuals with B cell lymphomas and multiple myeloma. We show that many of these individuals, despite markedly lower anti-spike IgG titers, rapidly develop potent infection neutralization capacities against several severe acute respiratory syndrome coronavirus 2 variants of concern (VoCs). The observed increased neutralization capacity per anti-spike antibody unit was paralleled by an early step increase in antibody avidity between the second and third vaccination. All individuals with hematologic malignancies, including those depleted of B cells and individuals with multiple myeloma, exhibited a robust T cell response to peptides derived from the spike protein of VoCs Delta and Omicron (BA.1). Consistently, breakthrough infections were mainly of mild to moderate severity. We conclude that COVID-19 vaccination can induce broad antiviral immunity including ultrapotent neutralizing antibodies with high avidity in different hematologic malignancies.